

Voluntary Modern Slavery Statement

Financial Year Ending: 31/03/2025

Company: Unicorn Pharmaceuticals Ltd

1. Commitment

Although **Unicorn Pharmaceuticals Ltd** is not required to publish a statement under Section 54 of the Modern Slavery Act 2015 due to turnover below £36 million, we voluntarily provide this statement to demonstrate our commitment to ethical conduct and responsible sourcing. We fully support the UK Government's objectives to eradicate modern slavery and human trafficking and expect the same standards from all organizations with whom we work.

We operate a **zero-tolerance approach** to slavery, forced labour, servitude, and human trafficking.

2. Organizational Structure and Activities

Unicorn Pharmaceuticals Ltd is a UK-based small pharmaceutical company engaged in marketing, distribution, and supply of pharmaceutical products, focusing on quality, value, and sustainability. We are licensed and regulated by the Medicines and Healthcare Products Regulatory Agency (MHRA).

The Company currently employs 4 staff and operates primarily within the United Kingdom.

3. Supply Chain Overview

Our suppliers may include:

- Licensed manufacturers
- Wholesalers and distributors
- Logistics contractors
- Professional service providers

We prioritize suppliers located within regulated jurisdictions (UK, EU, USA, and equivalent regulatory environments) and those operating under recognized quality or compliance standards.

4. Risk Assessment Approach

Due to the highly regulated nature of pharmaceutical manufacturing and distribution, we consider the inherent risk within our direct operations to be low, though we remain vigilant regarding indirect supply chain exposure. We adopt a **proportionate, risk-based approach** aligned to our size, structure, and operational scope.

Risk factors considered include:

- Country of operation
- Sector risk
- Nature of service or product
- Level of subcontracting
- Regulatory oversight

Where higher-risk factors are identified, enhanced checks may be undertaken before engagement or continuation of supplier relationships.

5. Policies Supporting Ethical Practice

We maintain internal policies designed to support ethical and lawful business conduct, including:

Unicorn Pharmaceuticals Limited

Devonshire House, 582 Honeypot Lane, Stanmore, HA7 1JS, United Kingdom

Registration Number: 14867894, VAT: 453 1947 84

www.unicornpharma.co.uk

- Code of Conduct
- Recruitment and Right-to-Work Verification Procedures
- Whistleblowing Policy
- Supplier Approval and Qualification Process
- Anti-Bribery and Corruption Policy

These policies are proportionate to our size and reviewed periodically.

6. Due Diligence and Supplier Assurances

We seek to ensure that suppliers:

- Operate in compliance with applicable labour laws
- Do not engage in forced labour or exploitative practices
- Maintain appropriate employment standards
- Provide evidence of regulatory licensing where applicable

Where appropriate, we may request written confirmation of compliance with modern slavery legislation or equivalent standards.

7. Reporting Concerns

Employees, contractors, and partners may raise concerns through internal reporting channels. All concerns are taken seriously, investigated appropriately, and handled confidentially where possible. We do not tolerate retaliation against individuals who raise concerns in good faith.

8. NHS and Public Sector Compliance Statement

In line with public sector procurement expectations, **Unicorn Pharmaceuticals Ltd confirms that:**

- We comply with applicable provisions of the Modern Slavery Act 2015 and all relevant employment legislation.
- We will cooperate with reasonable information requests from contracting authorities relating to ethical sourcing.
- We will notify contracting authorities promptly if any modern slavery risks are identified within our operations or supply chains.
- We will take appropriate corrective action if non-compliance is identified within our supply chain.
- We will maintain records demonstrating proportionate due diligence.
- We will support audit or assurance activities where reasonably requested.

9. Continuous Improvement

We are committed to improving our approach over time and will continue to:

- Review supplier risk periodically
- Update procedures where appropriate
- Monitor regulatory and procurement expectations
- Strengthen supplier engagement where risks are identified

10. Approval

This statement has been reviewed and approved by the Director of Unicorn Pharmaceuticals Ltd and constitutes the Company's modern slavery statement for the financial year ending 31 March 2025. This statement is available upon request.

Signed: _____
Name: Hemant Verma
Position: Director

Hemant
20/11/2025

Unicorn Pharmaceuticals Limited

Devonshire House, 582 Honeypot Lane, Stanmore, HA7 1JS, United Kingdom
Registration Number: 14867894, VAT: 453 1947 84
www.unicornpharma.co.uk